Free-flap reconstruction for large soft tissue defects is increasingly common, and plays an important role in the field of plastic and reconstructive surgery. 1 Minimizing flap failure is a key goal for any microsurgical unit. Data suggest that the commonest cause of failure is a problem with the venous anastomosis, occurring within the first 24 to 48 hours postoperatively. [2] [3] [4] This affects up to 20% of all free flap reconstructions, depending upon their location and entails significant physical, psychological, and emotional morbidity for patients. [5] [6] [7] Impending flap failure necessitates a further general anesthetic and reoperation, potentially out of hours, which
provides further logistical and practical challenges. 7 Venous congestion may require the use of medicinal leeches. It is very rare that leeches can salvage larger-sized flaps, and can also be highly unpleasant for patients, predisposing them to infection and anemia. 8, 9 Monitoring of Free Flaps and the Cook-Swartz Doppler Early recognition of flap compromise is the primary aim of every microsurgical unit. Prompt intervention and rescue is critical to salvage and ensuring flap survival. However, the complexities of free flap microcirculation are often difficult to assess, and there is a wide array of monitoring modalities. 10 The traditional method of monitoring is performed clinically and is based upon subjective clinical observations. These tests are performed typically on a "skin paddle" 11 and include assessment of color, capillary refill, temperature, turgor, and use of a handheld Doppler device. 1 Unlike solid organ transplantation, there is no objective assessment-such as decreased urine output in renal transplantation. Currently, there are no suitable imaging modalities for assessing microvascular flow and specifically slow venous flow problems, reports in the literature on the use of nuclear medicine techniques are largely experimental. 12 Early compromise, which entails the large majority of flap failure, is often asymptomatic. Skin changes can take a while to develop, potentially increasing ischemic times and reducing the possibility of successful salvage. 13 Some free flaps are more challenging to monitor, such as muscle flaps, those with dark skin or buried flaps within the head and neck.
The Cook-Swartz implantable Doppler (CSD) monitors the arterial or venous blood velocity from free flaps. 14 It is the only device currently on the market that allows such monitoring and is protected by patent. It consists of a 20 MHz ultrasonic Doppler crystal, a silicone cuff and a monitoring unit. 15, 16 This cuff secures the Doppler to the flap's vein or artery at the time of the operation and is placed downstream of the microvascular anastomosis. 16 The Doppler provides monitoring for 5 to 10 days postoperatively and is removed by simple traction. 14 Several studies have shown that use of this device increases success and salvage rates as it provides an earlier warning when compared with clinical monitoring. 11, 17, 18 Why it is Important to do this Systematic Review To our knowledge, there have only been two systematic reviews involving the CSD. 19, 28 Since then further studies have been published and this area is an active research front.
Objectives Primary Objective
To compare the efficacy of the CSD against clinical assessment (the traditional standard) in the detection of free-flap compromise.
Secondary Objectives
To determine the absolute indications for use of the Doppler (if any). Quantify positive and negative predictive values as well complications associated with the use of the CSD.
Methods
This systematic review was conducted in accordance with the Cochrane handbook for systematic reviews and reported in line with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement. 20 A protocol was published a priori. 21 
Inclusion and Exclusion Criteria

Types of Studies, Participants, Interventions, and Comparators
Studies comparing the use of the CSD with clinical assessment in detecting impending free-flap failure were included. Any article where the data were duplicated was excluded, as were articles not describing original data; such as editorials, letters, commentaries, and discussion pieces. There were no limitations on location of the flap or technique utilized.
Types of Outcome Measures
Primary Outcome Flap failure rate, defined as the number of free flaps lost divided by the total number of flaps performed.
Secondary Outcomes
Positive predictive value (PPV) and negative predictive values, time to detection will be reported where possible and compared between CSD and clinical groups. Any complications associated with CSD use will be described.
Search Methods for Identification of Studies
Electronic Searches
The following electronic databases were searched from 1966 until December 31, 2015: MEDLINE, EMBASE, PsycINFO, EBSCO, the Cochrane Library, CINAHL, SCOPUS, SciELO, NHS evidence, uptodate.com, clinicaltrials.gov, WHO meta-register of controlled trials (available at: who.int/ictrp/en), and controlled-trials.com.
Search Terms and Keywords
The search strategy was developed to locate articles related specifically to the CSD and provide evidence for the objectives previously stated. The search used the English language keywords combined with Boolean logical operators. The following terms were utilized without any limits: "Implantable doppler" OR "Cook-Swartz implantable doppler" OR "Cook-Swartz Implantable doppler" The search was not limited by language. Any non-English articles identified had their title and abstract screened and the full text was obtained if required. If full text was not available, then the authors were contacted to obtain an English language copy of the full text.
Other Resources
A hand search of the references of articles located by the search strategy was used to identify any additional relevant studies.
Selection of Studies
Studies identified by the electronic and manual search strategies were entered into a database. Results including citation, title, and abstracts were populated into EndNote (Thomson Reuters, New York, NY) and duplicates removed. Titles and abstracts were screened by two authors (B. G. and A. J. F.), any conflicts not resolvable between the two were referred to the lead author (R. A. A.) for resolution. Articles selected after title and abstract screen had their full text downloaded and a further assessment was made. Once the articles were selected for inclusion, data extraction took place.
Data Extraction and Management
Data were extracted independently by two authors (B. G. and A. J. F.) utilizing a standard extraction form where all data for each study were collated. Any conflicts were resolved by discussion; where resolution wasn't possible, the lead author (R. A. A.) made the final decision. These data were then entered into a Microsoft Excel 2011 database (Microsoft, Redmond, WA). Data collected constituted three main areas: 
Assessment of Study Quality and Bias in Included Studies
Quality of evidence was assessed using the Grading of Recommendation Assessment, Development and Evaluation (GRADE) system as proposed by Balshem et al. 22 Any information missing from the studies was documented and assessed to ascertain the risk of incomplete statistical sets.
Measures of Treatment Effect
The treatment effect was measured using an odds ratio for the studies, since the data were dichotomous (event vs. no event, where an event is a correctly identified flap necrosis or a true positive).
Dealing with Missing Data
Where data from studies were missing, the original investigators were contacted to request missing data. If this was not feasible, available data were analyzed and the potential impact of this is addressed in the discussion.
Assessment of Heterogeneity
Heterogeneity between studies was assessed using Higgins and Thompson I 2 , which measures the percentage variability in results attributable to heterogeneity between studies rather than sampling error. 23 Variability in the intervention effects in studies was tested for statistical heterogeneity utilizing Tau-squared (T 2 ), I 2 , and chi-squared ( 2 ) with corresponding p values calculated; the Cochrane tests.
The value of 2 statistics in the forest plot presents the assessment of whether the differences in results are compatible with chance alone. A large value of 2 test relative to its degree of freedom or a low p value indicates statistical variation (heterogeneity) beyond chance.
The I 2 percentage was interpreted as follows:
1. 0 to 30% may not be important 2. 30 to 60% may represent moderate heterogeneity a 3. 50 to 90% may represent substantial heterogeneity a 4. 75 to 100% represents considerable heterogeneity a Generation of statistical heterogeneity can be a consequence of clinical (participants, interventions, and outcomes) and/or methodological (study design and risk of bias) diversity or due to random error (chance) alone. T 2 represents the estimated standard deviation of underlying effects across studies. The exact model utilized for metaanalysis was based upon the level of heterogeneity within our data; with a random effects model used if substantial or considerable and a fixed-effects analysis if moderate, respectively.
Assessment of Reporting Biases
To ascertain if studies with negative outcomes are not being published ("publication bias"), we visually assessed funnel plot asymmetry. 23, 24 If both positive and negative results are published, the plot should resemble a symmetrical, inverted funnel. The precision of the estimated intervention effect increases as the size of the sample included in the study increases. Smaller studies therefore scatter widely at the bottom, with larger, more powerful studies grouping more narrowly at the top. assessment of heterogeneity was made. Based upon this a diagnostic test accuracy and review of a meta-analysis was performed comparing CSD to clinical monitoring using good quality observational studies.
Data Synthesis and Statistical Analysis
Rate of flap salvage was compared between modalities of monitoring to establish any correlation. The false positive and negative rates of the CSD were calculated.
Subgroup Analysis
Subgroup analyses were planned in our protocol as follows:
1. Different flap type (if > 3 studies describing specific flap types) 2. Venous versus Arterial CSD probe placement 3. Different anatomic locations (if > 3 studies describe the same anatomic locations)
However, as insufficient data were obtained, these subgroup analyses were not performed.
Results
Results of the Search
Following the electronic database search, 655 records were retrieved. After removing duplicates 251 records remained. The titles and abstracts of these studies were screened and 61 full-text articles were assessed for eligibility. Eight articles were deemed eligible for inclusion in the review. A summary of this process is displayed in ►Fig. 1.
Included Studies
Eight articles were included in the systematic review, involving 3,756 patients and 3,801 flaps. The average age of study participants was 48.1 years (though two did not report this) 25 and all but one of the studies attached the CSD distal to the venous anastomosis alone. The level of evidence as assessed by GRADE scoring was low or moderate for the included studies. 22 A summary of included studies is available in ►Table 1.
Effects of the Cook-Swartz Doppler
Primary Outcome
Flap failure rate was calculated for both CSD and clinically monitored flaps (►Table 2). The Ho et al 26 article was excluded, since it compared the CSD on high risk cases versus clinical monitoring on low cases. Frost et al 27 was excluded from qualitative synthesis since both the CSD and clinical monitoring groups also used microdialysis as an additional assessment and there was overlap between assessment methods in all groups. 
Meta-Analysis
A meta-analysis was performed using a random effects model as heterogeneity was substantial with I 2 ¼ 71% (►Fig. 2), this showed no significant difference between the two groups (p ¼ 0.87).
Sensitivity Analysis
When the article of Ho et al 26 was excluded, then heterogeneity was low (I 2 ¼ 33%) and a fixed-effects analysis showed there was a significant reduction in flap failure rate with CSD use (odds ratio ¼ 0.37, 95% confidence interval ¼ 0.21-0.64, p ¼ 0.0005) as seen in ►Fig. 3 below.
Secondary Outcomes
The sensitivity of clinical monitoring was calculated for six studies (►Table 3). The PPVs for CSD monitoring were estimable for seven of eight studies. These values ranged from 66.7 to 100%. As for the clinical monitoring group, Rozen et al 11 had a negative predictive value of 100% and two PPVs were calculated as 0.71 and 0.58. 2, 18 PPVs are shown in the table below for CSD only as there was insufficient data to calculate this for the clinical group (►Table 4).
Time to Detection
Four of the eight studies discussed, time to detection of flap compromise between clinical and CSD monitoring. Smit et al reported that the alteration of CSD signal was either before or at the same time as any clinical signs of flap compromise. 14 
Likewise, the study of Schmulder et al demonstrated that
there was a statistically significant relationship between flap outcomes and the time of discovering flow compromise between CSD and clinical monitoring, where many re-explorations in the CSD group were performed within the first 48 hours postoperatively, earlier than the clinical group. 2 Rozen et al noted that CSD use detected anastomotic insufficiency at an earlier time course than clinical monitoring in their study, with detection occurring many hours before clinical signs were evident. 11 Frost et al demonstrated that CSD was able to detect changes in the flap a mean of 97.5 minutes earlier than clinical assessment. 27 Complications were found to be infection and anastomotic insufficiency. 11 All other studies reported no complications related to CSD use.
Assessment of Reporting Biases
A funnel plot was generated, but with less than 10 studies, appropriate interpretation was not possible.
Discussion
Our analysis of over 3,800 flaps showed that flap monitoring with the CSD was superior to clinical monitoring when assessing flap failure rates (2.0 vs. 3.5%, respectively). The CSD was deployed across a wide range of settings including; head and neck, breast and limb reconstruction, and a wide variety of flaps types including; musculocutaneous, fasciocutaneous, and buried flaps. The PPV of the CSD was highly variable from 66.7 to 100% but negative predictive values were 90.9 to 100%. Frost et al was not included in our meta- analysis as the flaps in the study overlapped in their assessment methods. CSD, clinical and microdialysis was employed for the same flaps. 27 For these reasons, an accurate comparison between CSD and clinical assessments could not be made.
No studies specifically reported using the CSD in Fitzpatrick skin types 5 and 6, where traditional clinical monitoring techniques may be more difficult. The time critical nature of flap loss is clear. Schmulder et al found that the mean time to discovery of flap compromise was 1.333 days in the CSD group versus 2.423 days in the clinically monitored group. Linked to this, the same study reported a higher successful reexploration rate within and after 48 hours together with a lower failure rate in the CSD group. 2 However, the variability with which this was reported and the data provided precluded any attempts at data synthesis.
Overall, the quality of evidence available for synthesis was moderate or low, as assessed by GRADE and there were no randomized controlled trials (RCTs). One group undertook a prospective before and after study (Rozen et al) looking specifically at lower limb defects, however, with only 20 patients in each group, the findings of this study are more prone to bias than the larger studies, especially since a power calculation was not performed a priori. 11 However, this was also the only study amongst the six to undertake a baseline prognostic comparison of the two groups to assess for significant differences in; sex, age, smoking status, corticosteroid use, hypertension, diabetes mellitus, and mean ischemic time. Despite the best efforts to control two groups of patients for type of flap and type of patient, there could be anatomical confounders between the two groups.
Strengths of this Review
This was a carefully planned systematic review. Our group has performed several systematic reviews previously and has developed some expertise in this area. This is the first systematic review to look at the CSD. We asked a focused question and implemented strict inclusion and exclusion criteria to ensure only relevant articles of sufficient quality were included. Article selection and data extraction were performed independently by two researchers, and all decisions were finally authorized by the lead author (R. A. A.). We have reported our study in line with the PRISMA criteria and took every effort to ensure the review was performed with impartiality and minimum bias. Our selection of a binary outcome for our primary analysis (flap failure) nullifies issues often found in systematic reviews, such as the heterogeneous nature of outcomes and associated observer bias potentially confounding results. In addition, the problem with comparing PPVs for clinical and CSD-based monitoring is that the former is inevitably going to be more accurate-if one waits long enough, failure becomes clinically obvious. Earlier detection is likely to have played a key role in the difference in flap failure rates between the two groups.
Limitations
Despite our best efforts to locate appropriate studies, several potentially important studies could not be included as full texts were not available. Authors were contacted to try and access these, but we received no response. Moreover, the included studies did not account for the learning curve associated with the use of the CSD and with the use of venous couplers. We were also looking at studies comparing either clinical monitoring or CSD, not CSD in conjunction with clinical monitoring, which may provide optimal results. We comprehensively reviewed the available literature, including trial databases. However, no RCTs were available for inclusion in our study. The lack of data from the highest quality study methodology means a careful assessment of bias has to be undertaken.
The reporting of flap failure and adequate detection of flap compromise is complex with current reporting methods; however the flow diagram utilized by Rozen et al serves as a potentially useful template for future work. 16 The free flap failure rates were very low across all studies which may mean that only technically excellent high volume centers/surgeons are reporting their results, limiting external validity.
Cost-Effectiveness
If there is indeed a true benefit (subject to confirmation in a high-quality RCT or adequately powered prospective cohort studies), it is likely the CSD would be best deployed in high risk cases. Ho et al followed such a strategy, deploying the CSD in reoperations, those who had received radiotherapy, buried flaps, muscle flaps, those with very pale or very dark complexions, where there was difficult access for clinical monitoring or where there had been difficulties with intraoperative perfusion of the flap. 26 We can add significant comorbidities such as peripheral vascular disease and diabetes to this list, as well as smokers and surgeon choice-where their experience, intraoperative events or anatomical considerations necessitate closer adjunctive monitoring in addition to the routine clinical monitoring.
The cost of the CSD is U.S. $3,000 for the reusable base station and U.S. $300 for the disposable probes. With the clinical monitored group having an overall success rate of 96.5%, adding this marginal cost to every case may not be cost-effective but to a certain extent this depends on the balance of costs and reimbursements in the relevant health care system. Notwithstanding this, adding this marginal cost to the higher risk cases, as defined above, where flap failure is relatively more frequent is certainly a logical position. This strategy is supported by Rozen et al's study where they calculated the cost to salvage one flap at $20,000. 11
Future Directions
Further research is now required to determine the actual benefit of the CSD and the associated learning curve in its use. Ideally this would be in the format of a pragmatically designed RCT-at present there is equipoise for such a study. The use of the CSD may be highly beneficial in cross-specialty flaps, where patients may not be monitored by staff accustomed to free flaps, for example, where a patient returns to a nonplastic surgical ward after free flap surgery. A large observational cohort study, where specific flap types can be assessed with an appropriately powered cohort may well demonstrate important findings. A registry-based design may also be useful.
The other benefits of the CSD need to be quantified too if possible, such as the value of monitoring without waking the patient up at night or without having to use a mirror or flexible fiber optic to monitor a buried flap. This has to be weighed up against the more variable PPV-necessitating clinical correlation, hence its role is as an adjunct to clinical monitoring, not a replacement for it. We also call for further research to assess its cost-effectiveness.
Conclusion
Deployment of the CSD can lower flap failure rates and has the potential to be a useful adjunct to clinical monitoring of free flaps. Further research is needed to confirm its benefits and refine its indications to optimize cost-effectiveness. and A. J. F performed data collection for the review, undertook searches, screened search results, organized retrieval of articles, screened retrieved articles against eligibility criteria, appraised quality of articles and extracted data from articles. B. G. entered data into RevMan and analyzed data. B. G., A. J. F. and R. A. A. interpreted the data. All authors contributed to the writing of the article and its critical revision.
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